Effects of different doses of esketamine preemptive analgesia on immune function, inflammatory response and prognosis in breast cancer patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057226

Enrollment

Unknown

Registered

2022-03-04

Start date

2022-03-20

Completion date

Unknown

Last updated

2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

L-Esk group: low-dose esketamine group:Esketamine 0.25 mg/kg was administered 5 min before induction of anesthesia

M-Esk group: medium-dose esketamine group :Esketamine 0.5 mg/kg was administered 5 min before induction of anesthesi

H-Esk group: high-dose esketamine group:Esketamine 1 mg/kg was administered 5 min before induction of anesthesia

Group C: control group:Administer an equal dose of normal saline 5 min before induction of anesthesia

Eligibility

Sex/Gender

Female

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Female aged 30 to 65 years; 2. ASA classification I or II; 3. Body Mass Index (BMI) of 18-29 kg/m2; 4. Breast cancer patients who were diagnosed with breast cancer by mammography, puncture examination and breast color ultrasound and underwent unilateral radical mastectomy.

Exclusion criteria

Exclusion criteria: 1. Those who have had a history of breast surgery; 2. Patients diagnosed with inflammatory breast cancer; 3. Those with severe heart, lung, liver and kidney dysfunction; 4. Those with a history of opioid addiction; 5. Patients with metastatic breast tumors; 6. Those who received neoadjuvant chemotherapy before surgery; 7. Those with chronic pain disease; 8. Patients with mental illness; 9. Suffering from immune system diseases, or using drugs that have obvious effects on the immune system.

Design outcomes

Primary

Measure	Time frame
T lymphocyte subtypes (CD3+, CD4+ and CD8+);CD4+/CD8+ ratio and percentage of NK cells;Blood routine (peripheral blood neutrophil, lymphocyte, monocyte, platelet );Inflammatory cytokines: IL-6, IL-10, IL-1ß, TNF-a;	—

Secondary

Measure	Time frame
Record recurrence, metastasis and treatment;Anxiety, Depression;15-item quality of recovery rating scale, QoR-15;	—

Countries

China

Contacts

Public ContactXuexin Chen

Cancer Hospital of General Hospital of Ningxia Medical University

chenxuexin2637@163.com+86 13995001031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026